Figure EV1. mCD13‐AFR increases CAR T‐cell infiltration in SKOV3 tumors, and antigen specificity of hCD70 CAR T and mCD13‐AFR combination therapy.

• A
  Gating strategy for flow cytometric analysis of PBMCs in SKOV3 tumors. First, cell debris and bulk SKOV3 cells were gated out (“non‐debris”), then, PI‐positive dead cells were removed (“live”), and finally, doublets were gated out (“single cells”).
• B, C
  NSG mice were i.v. injected with 2.8 × 10⁶ CAR T cells on day 14 after tumor inoculation and treated p.l. with PBS (B) or 50 μg CD13‐AFR (C) on days 14, 15, 16, 25, 26, and 28 (n = 5). Flow cytometric analysis was performed on day 43. Human PBMCs were identified as hCD45 and hCD3 double positive cells (upper panel). The presence of the CAR transgene in human PBMCs was confirmed by eGFP expression (lower panel).
• D
  RL tumor growth in NSG mice after i.v. injection of 6 × 10⁶ hCD70 CAR T cells on day 14 and p.l. treatment with PBS or 50 μg mCD13‐AFR (↑). Tumor growth is shown as mean TSI, and error bars are SEM (n = 5).

Source data are available online for this figure.